Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733947) titled 'A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)' on July 24.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Caliway Biopharmaceuticals Co., Ltd.
Condition:
Subcutaneous Fat
Intervention:
Drug: CBL-514 Injection
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 2026
Target Sample Size: 300
Countries of Recruitment:
Unite...